News tagged with gastrointestinal stromal tumor
New technology spots drugs' early impact on cancer
A new preclinical technology enables researchers to quickly determine if a particular treatment is effective against gastrointestinal stromal tumors (GISTs), providing a boost to animal research and possibly patient care, ...
Cancer
Apr 09, 2013 |
not rated yet |
0
Blood tests can provide fuller picture of mutations in cancer than traditional biopsies do
A new blood test revealed more of the gene mutations that sustain certain digestive-tract tumors than did a DNA analysis of a traditional tumor biopsy, Dana-Farber Cancer Institute investigators will report at a special symposium ...
Cancer
Apr 07, 2013 |
not rated yet |
0
FDA expands approval of Bayer cancer drug (Update)
The U.S. Food and Drug Administration on Monday expanded approval of a Bayer cancer pill to treat tumors of the intestinal tract that do not respond to other treatments.
Medications
Feb 25, 2013 |
not rated yet |
0
Antibody hinders growth of Gleevec-resistant gastrointestinal tumors in lab tests
An antibody that binds to a molecule on the surface of a rare but deadly tumor of the gastrointestinal tract inhibits the growth of the cancer cells in mice, according to researchers at the Stanford University School of Medicine.
Cancer
Feb 04, 2013 |
4 / 5 (2) |
0
|
Expression, genomic patterns predict sarcoma progression
(HealthDay)—The Complexity Index in Sarcoma (CINSARC) and Genomic Index prognostic signatures are valid independent methods of assessing synovial sarcoma (SS) prognosis, according to a study published online ...
Cancer
Jan 18, 2013 |
not rated yet |
0
New drug overcomes resistance in patients with rare sarcoma
A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report ...
Cancer
Nov 21, 2012 |
5 / 5 (1) |
0
|
Clinical trial design supports original accelerated approval of sunitinib for GIST
Patients benefitted from an important design element in the pivotal phase III clinical trial that led to Food and Drug Administration and worldwide regulatory approval of sunitinib for the treatment of gastrointestinal stromal ...
Cancer
Jun 01, 2012 |
not rated yet |
0
Regorafenib active in metastatic GI stromal tumors
(HealthDay) -- Regorafenib, an inhibitor of multiple cancer-associated kinases, is active in patients with metastatic gastrointestinal stromal tumors (GIST) who have failed to respond to imatinib and sunitinib, ...
Cancer
May 23, 2012 |
not rated yet |
0
Longer treatment with cancer drug following removal of GI tumor results in improved survival
Among patients with a high risk of recurrence of a gastrointestinal stromal tumor following surgery for its removal, patients who received imatinib (a drug to treat certain cancers) for 3 years instead of 1 had improved recurrence-free ...
Cancer
Mar 27, 2012 |
not rated yet |
0
Novartis says EU approves expanded use of Glivec
Swiss pharmaceutical group Novartis said Monday the European Union will allow it to expand its use of the drug Glivec to treat certain rare forms of gastrointestinal cancer.
Medications
Feb 27, 2012 |
not rated yet |
0
Three 'targeted' cancer drugs raise risk of fatal side effects
Treatment with three relatively new "targeted" cancer drugs has been linked to a slightly elevated chance of fatal side effects, according to a new analysis led by scientists at Dana-Farber Cancer Institute. They added that ...
Cancer
Feb 06, 2012 |
5 / 5 (1) |
0
|
